Early treatment: PreCISe-ly what the patient needs.

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Multiple sclerosis (MS) typically starts in young adulthood with relapsing-remitting disease.
• Clinically isolated syndrome (CIS) is the first neurological episode, often preceding MS diagnosis.
• Early intervention in CIS with MRI lesions can significantly impact MS progression.

Purpose of the Study:

• To evaluate the efficacy of glatiramer acetate versus placebo in patients with CIS and MRI lesions.
• To assess the impact of early glatiramer acetate treatment on delaying conversion to clinically definite MS.
• To measure the effect of glatiramer acetate on disease burden in early MS.

Main Methods:

• Phase III multicentre, double-blind, randomised controlled trial (PreCISe trial).
• Participants: Patients with clinically isolated syndrome and abnormal MRI findings.
• Intervention: Glatiramer acetate versus placebo.

Main Results:

• Glatiramer acetate significantly delayed the progression to clinically definite multiple sclerosis.
• Treatment reduced the overall disease burden, evidenced by fewer new T2 lesions.
• T2 lesion volume was also significantly reduced in the glatiramer acetate group.

Conclusions:

• Glatiramer acetate is an effective first-line therapy for patients with CIS and MRI-detected lesions.
• Early treatment with glatiramer acetate modifies disease activity and delays MS conversion.
• This therapy represents a vital option for the earliest stages of multiple sclerosis management.